Imovane

Zopiclone, the active ingredient in Imovane, is a cyclopyrrolone presented as an oral tablet for systemic use. It acts as a hypnotic agent and is indicated for the short‑term management of insomnia in adult patients who have difficulty initiating or maintaining sleep. By positively modulating the GABA‑A receptor complex, it increases chloride ion influx, producing a sedative‑hypnotic effect that helps restore normal sleep patterns.

GNH USA supplies Imovane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zopiclone is a hypnotic agent used to manage sleep disorders.

- Insomnia: short‑term treatment to improve sleep onset and maintenance in adults. - Transient insomnia: helps patients achieve adequate sleep during brief periods of sleep disturbance. - Primary insomnia: facilitates restoration of normal sleep patterns in individuals with chronic difficulty sleeping.

Zopiclone may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Drowsiness: feeling unusually sleepy during the day. - Dry mouth: reduced salivation causing discomfort. - Bitter or metallic taste: unpleasant oral sensation. - Headache: mild to moderate cranial pain. - Dizziness: sensation of light‑headedness or unsteadiness. - Gastrointestinal upset: nausea, abdominal discomfort, or dyspepsia.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Complex sleep behaviors: sleepwalking, sleep‑driving, or other activities performed while not fully awake. - Memory impairment: difficulty recalling events that occurred after dosing. - Mood changes: depression, anxiety, or suicidal thoughts. - Respiratory depression: slowed breathing, especially when combined with other depressants. - Dependence or withdrawal: symptoms upon abrupt discontinuation after prolonged use.

Before prescribing Zopiclone, clinicians should consider several safety measures. - Assess duration of insomnia: limit use to short‑term periods to reduce dependence risk. - Use lowest effective dose: start with the minimal dose that provides therapeutic benefit. - Avoid alcohol: concurrent consumption can potentiate sedative effects. - Caution in hepatic impairment: liver dysfunction may increase drug exposure. - Monitor for dependence: watch for signs of tolerance or withdrawal. - Store below 25°C: keep in the original pack, protect from moisture.

Zopiclone can interact with other substances that affect the central nervous system or its metabolism.

Major Interactions (Avoid): - Alcohol: additive CNS depression leading to excessive sedation. - Other CNS depressants (e.g., opioids, barbiturates): heightened risk of respiratory depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increased plasma concentrations of Zopiclone.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduced efficacy due to lower drug levels. - Antidepressants (e.g., SSRIs, SNRIs): potential for enhanced sedation. - Antihistamines: may increase drowsiness. - Grapefruit juice: can modestly raise Zopiclone exposure. - Antihypertensives: possible additive hypotensive effect.